Catherine J Wu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3999026/publications.pdf

Version: 2024-02-01

221 papers	36,484 citations	16791 66 h-index	4305 179 g-index
231 all docs	231 docs citations	231 times ranked	47281 citing authors

#	Article	IF	Citations
1	The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Advances, 2023, 7, 145-158.	2.5	15
2	Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nature Biotechnology, 2022, 40, 209-217.	9.4	127
3	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood, 2022, 139, 686-689.	0.6	29
4	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	2.5	12
5	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	2.9	40
6	Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood, 2022, 139, 2252-2256.	0.6	7
7	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 279-291.	5.1	118
8	Tumor-Infiltrating T Cells â€" A Portrait. New England Journal of Medicine, 2022, 386, 992-994.	13.9	10
9	cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. Nature Communications, 2022, 13, 1698.	5.8	33
10	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. Journal of Clinical Investigation, 2022, 132, .	3.9	48
11	Report of the First International Symposium on NUT Carcinoma. Clinical Cancer Research, 2022, 28, 2493-2505.	3.2	23
12	Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clinical Cancer Research, 2022, 28, 3356-3366.	3.2	13
13	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology, 2022, 40, 2913-2923.	0.8	40
14	Reinvigorating therapeutic cancer vaccines. Current Opinion in Immunology, 2022, 76, 102176.	2.4	3
15	Mass Spectrometry Based Identification of Novel HLA Class I Restricted Peptides in Merkel Cell Carcinoma. FASEB Journal, 2022, 36, .	0.2	0
16	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature, 2022, 605, 532-538.	13.7	70
17	Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. Frontiers in Immunology, 2022, 13, .	2.2	1
18	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precision Oncology, 2022, , .	1.5	11

#	Article	IF	Citations
19	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	3.2	12
20	Cancer vaccines: Building a bridge over troubled waters. Cell, 2022, 185, 2770-2788.	13.5	82
21	Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. Journal of Clinical Investigation, 2022, 132, .	3.9	10
22	Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nature Biotechnology, 2021, 39, 451-461.	9.4	150
23	Frontiers in cancer immunotherapyâ€"a symposium report. Annals of the New York Academy of Sciences, 2021, 1489, 30-47.	1.8	39
24	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
25	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discovery, 2021, 2, 54-69.	2.6	16
26	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 352-364.	2.5	58
27	Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Molecular and Cellular Proteomics, 2021, 20, 100133.	2.5	32
28	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nature Medicine, 2021, 27, 515-525.	15.2	248
29	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances, 2021, 5, 861-871.	2.5	23
30	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine, 2021, 13, .	5.8	54
31	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	5.8	84
32	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood, 2021, 137, 3212-3217.	0.6	24
33	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell, 2021, 39, 380-393.e8.	7.7	27
34	Splice it up: Atypical transcripts to boost leukemia immunotherapy. Immunity, 2021, 54, 608-610.	6.6	1
35	Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discovery, 2021, 11, 2266-2281.	7.7	42
36	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230

#	Article	IF	Citations
37	60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Research, 2021, 81, 4373-4384.	0.4	19
38	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discovery, 2021, 11, 3048-3063.	7.7	31
39	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	3.2	10
40	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature, 2021, 596, 119-125.	13.7	239
41	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clinical Cancer Research, 2021, 27, 5062-5071.	3.2	8
42	Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nature Cancer, 2021, 2, 758-772.	5.7	52
43	Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Advances, 2021, 5, 4701-4709.	2.5	12
44	Allogeneic hematopoietic cell transplantation outcomes in patients with Richterâ€™s transformation. Haematologica, 2021, 106, 3219-3222.	1.7	15
45	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 2982-2986.	2.5	45
46	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Advances, 2021, 5, 5140-5149.	2.5	21
47	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	5.8	15
48	Targeting constitutively active <scp>STAT3</scp> in chronic lymphocytic leukemia: A clinical trial of the <scp>STAT3</scp> inhibitor pyrimethamine with pharmacodynamic analyses. American Journal of Hematology, 2021, 96, E95-E98.	2.0	17
49	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
50	Beyond conventional immune-checkpoint inhibition â€" novel immunotherapies for renal cell carcinoma. Nature Reviews Clinical Oncology, 2021, 18, 199-214.	12.5	179
51	Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System. Molecular Cancer Research, 2021, 19, 623-635.	1.5	24
52	Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discovery, 2021, 2, 13-18.	2.6	5
53	Activation of Notch and Myc Signaling via B-cellâ€"Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Research, 2021, 81, 6117-6130.	0.4	10
54	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	3.2	0

#	Article	IF	Citations
55	Mapping the evolution of TÂcell states during response and resistance to adoptive cellular therapy. Cell Reports, 2021, 37, 109992.	2.9	37
56	Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics. Frontiers in Immunology, 2021, 12, 788891.	2.2	12
57	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. Frontiers in Oncology, 2021, 11, 790004.	1.3	11
58	Understanding CLL biology through mouse models of human genetics. Blood, 2021, 138, 2621-2631.	0.6	11
59	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	3.2	6
60	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica, 2020, 105, 1379-1390.	1.7	24
61	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nature Biotechnology, 2020, 38, 199-209.	9.4	324
62	Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clinical Cancer Research, 2020, 26, 1359-1371.	3.2	90
63	High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome Biology, 2020, 21, 266.	3.8	23
64	Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunology Research, 2020, 8, 1465-1469.	1.6	20
65	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	2.5	22
66	Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Research, 2020, 80, 4854-4867.	0.4	11
67	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Science Translational Medicine, 2020, 12, .	5.8	17
68	A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nature Medicine, 2020, 26, 792-802.	15.2	381
69	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020, 135, 2182-2191.	0.6	62
70	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
71	Delineating the evolutionary dynamics of cancer from theory to reality. Nature Cancer, 2020, 1, 580-588.	5.7	29
72	Robust Antiâ€Tumor T Cell Response with Efficient Intratumoral Infiltration by Nanodisc Cancer Immunotherapy. Advanced Therapeutics, 2020, 3, 2000094.	1.6	11

#	Article	IF	Citations
73	Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nature Communications, 2020, 11, 1438.	5.8	273
74	CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia, 2020, 34, 1599-1612.	3.3	21
75	Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discovery, 2020, 10, 185-197.	7.7	68
76	Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Scientific Reports, 2020, 10, 723.	1.6	21
77	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. Journal of Clinical Investigation, 2020, 130, 1595-1607.	3.9	10
78	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant NaÃ¯ve Settings. Blood, 2020, 136, 15-17.	0.6	9
79	RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model. Blood, 2020, 136, 28-29.	0.6	4
80	Expression of Sf3b1-K700E accelerates the Development of Chronic Lymphocytic Leukemia in a Del(13q) Murine Model. Blood, 2020, 136, 4-5.	0.6	1
81	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 34-35.	0.6	1
82	Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial. Blood, 2020, 136, 8-9.	0.6	4
83	Genetic Determinants and Evolutionary History of Richter's Syndrome. Blood, 2020, 136, 47-48.	0.6	3
84	Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter's Syndrome. Blood, 2020, 136, 2-3.	0.6	1
85	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13.	0.6	0
86	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. Blood, 2020, 136, 3-4.	0.6	2
87	Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution. Blood, 2020, 136, 12-13.	0.6	0
88	IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-9.	0.6	10
89	RNase Hâ€“dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nature Protocols, 2019, 14, 2571-2594.	5.5	23
90	SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunology Research, 2019, 7, 1485-1496.	1.6	34

#	Article	IF	Citations
91	Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncology, 2019, 5, 1631.	3.4	166
92	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell, 2019, 36, 369-384.e13.	7.7	224
93	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80
94	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell, 2019, 35, 283-296.e5.	7.7	71
95	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature, 2019, 570, 474-479.	13.7	86
96	Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature, 2019, 569, 576-580.	13.7	195
97	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature Communications, 2019, 10, 1874.	5.8	63
98	Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discovery, 2019, 9, 476-481.	7.7	48
99	Dissecting CLL through high-dimensional single-cell technologies. Blood, 2019, 133, 1446-1456.	0.6	5
100	Clonal dynamics in chronic lymphocytic leukemia. Blood Advances, 2019, 3, 3759-3769.	2.5	23
101	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunology, Immunotherapy, 2019, 68, 421-432.	2.0	93
102	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565, 234-239.	13.7	956
103	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal of Hematology, 2019, 94, 446-454.	2.0	56
104	Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading. , 2019, , .		3
105	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-NaÃ¯ve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. Blood, 2019, 134, 2015-2015.	0.6	3
106	Clonal dynamics in chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2019, 2019, 466-475.	0.9	0
107	Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discovery, 2018, 8, 730-749.	7.7	367
108	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113

#	Article	IF	Citations
109	High-dimension single-cell analysis applied to cancer. Molecular Aspects of Medicine, 2018, 59, 70-84.	2.7	19
110	Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18, 168-182.	10.6	736
111	Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Medicine, 2018, 10, 87.	3.6	51
112	DeTiN: overcoming tumor-in-normal contamination. Nature Methods, 2018, 15, 531-534.	9.0	71
113	Immunotherapy for glioblastoma: going viral. Nature Medicine, 2018, 24, 1094-1096.	15.2	25
114	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood, 2018, 132, 1911-1921.	0.6	44
115	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight, 2018, 3, .	2.3	39
116	A Novel Approach To Identify Genetic Signatures Of Clinical Outcome To Ipilimumab. , 2018, , .		0
117	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 820-820.	0.6	0
118	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026740.	2.9	25
119	Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 2017, 3, 16096.	18.1	363
120	Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecologic Oncology Reports, 2017, 19, 42-45.	0.3	24
121	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity, 2017, 46, 197-204.	6.6	400
122	Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity, 2017, 46, 315-326.	6.6	596
123	Correction: Chronic lymphocytic leukaemia. Nature Reviews Disease Primers, 2017, 3, 17008.	18.1	82
124	Phosphatidylinositol 3-kinase Î´ blockade increases genomic instability in B cells. Nature, 2017, 542, 489-493.	13.7	105
125	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	8
126	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	13.5	1,742

#	Article	IF	Citations
127	HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell, 2017, 32, 1-3.	7.7	8
128	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	13.7	2,112
129	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Research, 2017, 27, 1300-1311.	2.4	67
130	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nature Communications, 2017, 8, 2185.	5.8	148
131	SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell, 2017, 32, 716-716.e1.	7.7	9
132	MCVdb: A database for knowledge discovery in Merkel cell polyomavirus with applications in T cell immunology and vaccinology. , 2017, , .		1
133	Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2017, 35, 984-993.	0.8	44
134	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports, 2016, 15, 857-865.	2.9	671
135	Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell, 2016, 30, 404-417.	7.7	318
136	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. New England Journal of Medicine, 2016, 375, 143-153.	13.9	488
137	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications, 2016, 7, 11589.	5.8	285
138	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell, 2016, 30, 750-763.	7.7	173
139	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	9.4	288
140	Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. Clinical Cancer Research, 2016, 22, 1547-1549.	3.2	10
141	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science, 2016, 351, 1463-1469.	6.0	2,445
142	Single Cell Bisulfite Sequencing Defines Epigenetic Diversification in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 1047-1047.	0.6	1
143	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. Blood, 2016, 128, 188-188.	0.6	3
144	Dynamic Alterations in Gene Expression in Ibrutinib Treated CLL Reveal Profound Impact on Multiple Signaling Pathways. Blood, 2016, 128, 189-189.	0.6	3

#	Article	IF	Citations
145	Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood, 2015, 126, 445-453.	0.6	126
146	The Cyclophilin Aâ€“CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nature Medicine, 2015, 21, 572-580.	15.2	79
147	Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell, 2015, 160, 48-61.	13.5	2,948
148	Association of Polymerase eâ€“Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncology, 2015, 1, 1319.	3.4	523
149	Haematological malignancies: at the forefront of immunotherapeutic innovation. Nature Reviews Cancer, 2015, 15, 201-215.	12.8	63
150	Mutations driving CLL and their evolution in progression and relapse. Nature, 2015, 526, 525-530.	13.7	868
151	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 2015, 350, 207-211.	6.0	2,275
152	Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nature Biotechnology, 2015, 33, 1152-1158.	9.4	573
153	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). Blood, 2015, 126, 543-543.	0.6	8
154	Understanding anti-leukemia responses to donor lymphocyte infusion. OncoImmunology, 2014, 3, e28187.	2.1	18
155	Personal neoantigen cancer vaccines. OncoImmunology, 2014, 3, e29311.	2.1	55
156	Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. Cancer Cell, 2014, 26, 813-825.	7.7	323
157	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood, 2014, 124, 453-462.	0.6	286
158	Somatic mutation as a mechanism of Wnt/Î²-catenin pathway activation in CLL. Blood, 2014, 124, 1089-1098.	0.6	65
159	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	0.6	164
160	Evolving Understanding of the CLL Genome. Seminars in Hematology, 2014, 51, 177-187.	1.8	24
161	Vaccines and Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 559-569.	0.9	20
162	HLA-Binding Properties of Tumor Neoepitopes in Humans. Cancer Immunology Research, 2014, 2, 522-529.	1.6	194

#	Article	IF	Citations
163	Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. Journal of Clinical Investigation, 2014, 124, 4681-4683.	3.9	3
164	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood, 2014, 123, 1412-1421.	0.6	78
165	CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunology, Immunotherapy, 2013, 62, 347-357.	2.0	47
166	Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Medicine, 2013, 5, 47.	3.6	41
167	SF3B1 mutations in chronic lymphocytic leukemia. Blood, 2013, 121, 4627-4634.	0.6	103
168	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell, 2013, 152, 714-726.	13.5	1,202
169	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	13.7	4,761
170	Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer Immunology Research, 2013, 1, 11-15.	1.6	167
171	Boosting leukemia-specific T cell responses in patients following stem cell transplantation. OncoImmunology, 2013, 2, e26587.	2.1	2
172	Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. Journal of Clinical Investigation, 2013, 123, 3756-3765.	3.9	69
173	SF3B1 Mutation Alters The Selection Of 3' RNA Splice Sites In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 117-117.	0.6	2
174	Reconstructing a Genotype-Phenotype Map In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2857-2857.	0.6	1
175	Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution. Blood, 2013, 122, 596-596.	0.6	4
176	Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period. Blood, 2013, 122, 4618-4618.	0.6	0
177	Detecting T-cell reactivity to whole cell vaccines. OncoImmunology, 2012, 1, 1095-1103.	2.1	14
178	Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2012, 18, 3791-3802.	3.2	76
179	Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients. Clinical Cancer Research, 2012, 18, 5761-5772.	3.2	57
180	Applications of Next-Generation Sequencing to Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S151-S160.	2.0	20

#	Article	IF	Citations
181	Functional Somatic and Germline Variants in the NF-Î¹B Pathway in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 560-560.	0.6	7
182	Somatic Mutation As a Mechanism of Wnt/Î²-Catenin Pathway Activation in CLL. Blood, 2012, 120, 559-559.	0.6	0
183	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1892-1892.	0.6	0
184	Understanding the Role of Mutations in SF3B1 and Splicing in Chronic Lymphocytic Leukemia. Blood, 2012, 120, SCI-15-SCI-15.	0.6	1
185	Reversal of T Cell Exhaustion in Pre-Treatment Marrow T Cells Is Associated with Effective Graft-Versus-Leukemia Responses to Donor Lymphocyte Infusion. Blood, 2012, 120, 1903-1903.	0.6	0
186	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4567-4567.	0.6	0
187	The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 5-5.	0.6	1
188	SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2011, 365, 2497-2506.	13.9	1,021
189	In mixed hematopoietic chimerism, the donor red cells win. Haematologica, 2011, 96, 13-15.	1.7	34
190	Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acidâ€“immunoglobulin complexes in humans. Journal of Clinical Investigation, 2011, 121, 1574-1584.	3.9	17
191	Sensitivity to Wnt Pathway Inhibition in CLL Is Associated with Specific Gene Expression Signatures. Blood, 2011, 118, 801-801.	0.6	1
192	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 465-465.	0.6	0
193	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. Blood, 2011, 118, 463-463.	0.6	0
194	Graft-versus-Leukemia Antigen CML66 Elicits Coordinated B-Cell and T-Cell Immunity after Donor Lymphocyte Infusion. Clinical Cancer Research, 2010, 16, 2729-2739.	3.2	37
195	Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor Cells. Cancer Research, 2010, 70, 906-915.	0.4	52
196	Marrow-Infiltrating T Cells In Patients with Chronic Lymphocytic Leukemia Display Markers of Functional Impairment and Express PD-1. Blood, 2010, 116, 2417-2417.	0.6	0
197	Revealing Tumor Immunity after Hematopoietic Stem Cell Transplantation. Clinical Cancer Research, 2009, 15, 4515-4517.	3.2	8
198	Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B and T Cell Immunity After Donor Lymphocyte Infusion.. Blood, 2009, 114, 2449-2449.	0.6	0

#	Article	IF	Citations
199	Erythroid-lineageâ€“specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2008, 36, 1205-1215.	0.2	10
200	Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2008, 14, 1270-1278.	2.0	120
201	Stem Cell Transplantation for Hemoglobinopathies. , 2008, , 201-221.		0
202	Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. British Journal of Haematology, 2007, 139, 504-507.	1.2	52
203	Induction of Tumor Immunity Following Allogeneic Stem Cell Transplantation. Advances in Immunology, 2006, 90, 133-173.	1.1	72
204	Monitoring Imatinib Resistance with a â€œPolonyâ€•Assay: Towards Tailored Therapy of Chronic Myelogenous Leukemia (CML).. Blood, 2006, 108, 837-837.	0.6	1
205	Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9.. Blood, 2006, 108, 188-188.	0.6	0
206	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood, 2005, 105, 2973-2978.	0.6	361
207	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood, 2005, 105, 3945-3950.	0.6	94
208	Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood, 2005, 106, 3639-3645.	0.6	79
209	Graft-versus-Leukemia Target Antigens in Chronic Myelogenous Leukemia Are Expressed on Myeloid Progenitor Cells. Clinical Cancer Research, 2005, 11, 4504-4511.	3.2	54
210	Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment.. Blood, 2005, 106, 3172-3172.	0.6	5
211	Post-Transplant Monitoring of Erythroid Lineage Specific Chimerism.. Blood, 2005, 106, 5233-5233.	0.6	0
212	Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.. Blood, 2005, 106, 3105-3105.	0.6	3
213	A Novel Mechanism of Alternative Promoter and Splicing Regulates the Epitope Generation of Tumor Antigen CML66-L. Journal of Immunology, 2004, 172, 651-660.	0.4	37
214	Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood, 2004, 103, 656-663.	0.6	73
215	Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.. Blood, 2004, 104, 1679-1679.	0.6	8
216	Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Experimental Hematology, 2003, 31, 924-933.	0.2	27

#	Article	IF	Citations
217	Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood, 2002, 99, 4610-4617.	0.6	78
218	Quantitative Monitoring of BCR / ABL Transcript During STI-571 Therapy. Leukemia and Lymphoma, 2002, 43, 2281-2289.	0.6	14
219	Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biology of Blood and Marrow Transplantation, 2002, 8, 625-632.	2.0	107
220	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Research, 2002, 62, 5517-5522.	0.4	68
221	Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. Journal of Clinical Investigation, 2000, 106, 705-714.	3.9	121